fruquintinib
fruquintinib: 9 clinical trials tracked.
fruquintinib evidence translation
What we can confirm
9 tracked trials
What it means
What to watch
Prepared research question
What is verified about fruquintinib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 5 study sponsors
Related indications
Clinical Trials (9)
A Phase II, Open-label, Non-comparative, Randomized Study of Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
Primary endpoint: Disease Control Rate (DCR)
A Phase II Study Investigating Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
Primary endpoint: Progression-Free Survival (PFS) rate at 6 months
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
Primary endpoint: Safety and adverse events (AEs)
A Single Arm Phase 4 Trial to Evaluate the Safety and Efficacy of Oral Fruquintinib in the Treatment of Refractory Metastatic Colorectal Cancer in Patients From Minority Populations Underrepresented in Prior Fruquintinib Studies
Primary endpoint: Number of Participants with Treatment Emergent Grade 3 and Grade 4 Hypertension
A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASKG915 in Patients With Selected Advanced Solid Tumors
Primary endpoint: Dose limiting toxicities (DLTs)
A Phase 1-2 Dose-escalation and Expansion Study of ST316 in Subjects With Selected Advanced Unresectable and Metastatic Solid Tumors
Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
An Open-Label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Primary endpoint: Part 1: Number of Patients With Dose-Limiting Toxicities (DLTs)
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Primary endpoint: Overall Survival (OS)
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies
Primary endpoint: Number of Participants with Immune-Mediated Adverse Events, Serious Adverse Events, and Adverse Events Grade 3 or Higher